Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels

References

• Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008;115:141–50.
   PubMed Web of Science ®Google Scholar
• Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014;5:211–18.
   PubMedGoogle Scholar
• Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:195–203.
   PubMed Web of Science ®Google Scholar
• Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010;42:320–30.
   PubMedGoogle Scholar
• Koppe SW. Obesity and the liver: nonalcoholic fatty liver disease. Transl Res 2014;164:312–22.
   PubMed Web of Science ®Google Scholar
• Mirza MS. Obesity, visceral fat, and NAFLD: querying the role of adipokines in the progression of nonalcoholic fatty liver disease. ISRN Gastroenterol 2011;2011:592404.
   PubMedGoogle Scholar
• Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679–89.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Senates E, Ayyildiz T, Colak Y, Tuncer I, Ovunc AO, et al. Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. Eur J Clin Invest 2012;42:411–18.
   PubMed Web of Science ®Google Scholar
• Patell R, Dosi R, Joshi H, Sheth S, Shah P, Jasdanwala S. Non-alcoholic fatty liver disease (NAFLD) in obesity. J Clin Diagn Res 2014;8:62–6.
   Google Scholar
• Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr 2013;162:496–500.
   PubMed Web of Science ®Google Scholar
• Corrado RL, Torres DM, Harrison SA. Review of treatment options for nonalcoholic fatty liver disease. Med Clin North Am 2014;98:55–72.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–23.
   PubMed Web of Science ®Google Scholar
• Vos B, Moreno C, Nagy N, Féry F, Cnop M, Vereerstraeten P, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol Belg 2011;74:389–94.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012;91:319–27.
   PubMed Web of Science ®Google Scholar
• Dela Cruz AC, Bugianesi E, George J, Day CP, Liaquat H, Charatcharoenwitthaya P, et al. Characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease [abstract 379]. DDW 2014, Chicago, IL, USA.
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, Brewer HBJr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–21.
   PubMed Web of Science ®Google Scholar
• Trak-Smayra V, Dargere D, Noun R, Albuquerque M, Yaghi C, Gannagé-Yared MH, et al. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut 2009;58:825–32.
   PubMed Web of Science ®Google Scholar
• Xu L, Xu CF, Yu CH, Miao M, Li YM. Haemoglobin and non-alcoholic fatty liver disease: further evidence from a population-based study. Gut 2009;58:1706–7.
   PubMed Web of Science ®Google Scholar
• Yu C, Xu C, Xu L, Yu J, Miao M, Li Y. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol 2012;56:241–7.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zeng J, Chen B. Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver. J Gastroenterol Hepatol 2014;29:1508–14.
   PubMed Web of Science ®Google Scholar
• Bai CH, Wu MS, Owaga E, Cheng SY, Pan WH, Chang JS. Relationship between hemoglobin levels and risk for suspected non-alcoholic fatty liver in Taiwanese adults. Chin J Physiol 2014;57:5.
   Web of Science ®Google Scholar
• Liu W, Baker SS, Baker RD, Nowak NJ, Zhu L. Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis. PLoS One 2011;6:e24363.
   PubMed Web of Science ®Google Scholar
• Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007;102:1251–8.
   PubMed Web of Science ®Google Scholar
• Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;37:720–9.
   PubMed Web of Science ®Google Scholar
• Huang CH, Chang CC, Kuo CL, Huang CS, Chiu TW, Lin CS, et al. Serum iron concentration, but not hemoglobin, correlates with TIMI risk score and 6-month left ventricular performance after primary angioplasty for acute myocardial infarction. PLoS One 2014;9:e104495.
   Web of Science ®Google Scholar
• Yoneda M, Thomas E, Sumida Y, Imajo K, Eguchi Y, Hyogo H, et al. Clinical usage of serum ferritin to assess liver fibrosis in patients with nonalcoholic fatty liver disease: proceed with caution. Hepatol Res 2014; Epub ahead of print.
   Web of Science ®Google Scholar
• Shen J, Wong GL, Chan HL, Chan HY, Yeung DK, Chan RS, et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther 2014;39:532–9.
   PubMed Web of Science ®Google Scholar